Fig. 3
Gene expression of BCL2 and PLC genes in MDS patients. A BCL2 gene expression in cells obtained from MDS patients at baseline (T0), after 4 (T4) and 8 (T8) cycles of AZA + LEN therapy. Responder patients (R) show high levels of BCL2 at T0, T4 and T8, as compared to healthy subjects (HD), increasing levels at T4 (vs T0) and a reduction at T8 (vs T4). Patients losing response (LR) show high levels at T0 (statistically significant), T4 and T8 as compared to healthy subjects (HD), a constant amount at T4 (vs T0) and a slight reduction at T8 (vs T4). Non-responder (NR) patients show high levels of BCL2 at T0, T4 and T8, whose difference with healthy subjects (HD) is always statistically significant. During treatment, the amount of BCL2 in NR is slightly reduced. B PLCB1 expression in MDS patients at baseline (T0), after 4 (T4) and 8 (T8) cycles of AZA + LEN therapy. All patients’ subgroups [responders (R), losing response (LR), and non-responders (NR)] show higher levels of PLCB1, that are not statistically different from healthy subjects (HD). At T4, all patients’ subgroups show a slight induction (as compared with T0) and a subsequent reduction at T8 (vs T4), with LR and NR subgroups always showing higher levels than R. C PLCG1 expression in MDS patients at baseline (T0), after 4 (T4) and 8 (T8) cycles of AZA + LEN therapy. All patients’ subgroups [responders (R), losing response (LR), and non-responders (NR)] show higher levels of PLCG1, that are not statistically different from healthy subjects (HD). At T4, LR and NR subgroups show a reduction, while R display a slight increase, as compared with T0 (not statistically significant). At T8, R and NR show a reduction and LR display a slight increase, as compared with T4 (not statistically significant). All data are represented as mean ± SD. Each experiment was repeated at least three times, with at least six replicates for each treatment condition and patients’ subgroup. *p < 0.05 versus HD, by one-way ANOVA using Bonferroni multiple comparisons in GraphPad Prism 5